CapeXL is an end-to-end solution for personalised cancer treatment, providing next-generation sequencing (NGS), analysis, annotation and reporting to clinicians.
The service is patient-focused, matching individuals to the latest options in treatment including approved drugs, drugs with evidence in early and late stage clinical trials and pre-clinical models approved for cancers.
We make ordering and reporting simple for clinicians, so they can support their patients in a personalised way.
Whole genome sequencing (WGS) supports better patient outcomes with the complete picture and detecting variants precisely.
A 2018 study found WGS improves “comprehensiveness and accuracy” of variant detection, cancer treatment and outcomes. *